Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(32 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama Mayo Clinic Cancer Center, Phoenix, Arizona University of California, San Diego, La Jolla, California University of Southern California, Los Angeles, California University Of California, Irvine, Orange, California Stanford Cancer Institute, Palo Alto, California UCLA Santa Monica Medical Center, Santa Monica, California University of Colorado Cancer Center, Aurora, Colorado Sarah Cannon Research Institute, Denver, Colorado Yale University School of Medicine, New Haven, Connecticut Mayo Clinic Cancer Center, Jacksonville, Florida University of Miami, Miami, Florida Northwestern University, Chicago, Illinois University of Iowa, Iowa City, Iowa Johns Hopkins University, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Harvard University, Boston, Massachusetts University of Michigan, Ann Arbor, Michigan Mayo Clinic Cancer Center, Rochester, Minnesota Memorial Sloan-Kettering Cancer Center, New York, New York Duke University Medical Center, Durham, North Carolina Ohio State University, Columbus, Ohio Oregon Health & Science University, Portland, Oregon Thomas Jefferson University, Philadelphia, Pennsylvania Temple University Health System, Philadelphia, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee Vanderbilt University Medical Center, Nashville, Tennessee Sarah Cannon Research Institute, Dallas, Texas University of Texas, Houston, Texas University of Texas Health Science Center, San Antonio, Texas University of Utah, Salt Lake City, Utah Medical College of Wisconsin, Milwaukee, Wisconsin